Lyceryl-Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. The synergistic action of these agents helps achieve optimal glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Lyceryl-Forte Tablet PR is formulated as a prolonged-release tablet to ensure sustained drug release, promoting better compliance and minimizing fluctuations in plasma drug concentrations. It is recommended to be administered once daily with meals to reduce gastrointestinal side effects commonly associated with Metformin. Clinical use requires regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, and gastrointestinal disturbances. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and hypersensitivity to any component. This combination therapy should be prescribed under medical supervision, with dosage adjustments based on therapeutic response and patient tolerance to optimize diabetes management and reduce the risk of long-term complications.